United Kingdom (UK)
Recombinant monoclonal antibody to HbA1c. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1G8.
UniProt Accession Number of Target Protein: P68871
Alternative Name(s) of Target: GHb; A1C; HBB; hemoglobin A1c; glycosylated hemoglobin HbA1c; glycosylated hemoglobin; glycohemoglobin; glycated hemoglobin; haemoglobin; haemoglobin A1c; Hemoglobin subunit beta; Beta-globin; Hemoglobin beta chain
Immunogen: The original antibody was generated by immunizing BALB/c mice with synthetic N-terminal glycopeptide (VHLTPEC) and KLH conjugate.
Specificity: This antibody binds human hemoglobin glycated at the N-terminal valine of the hemoglobin β chain and does not cross react with non-glycated hemoglobin. Glycated hemoglobin is formed by the conjugation of a hexose sugar to the beta-chain of hemoglobin. Glycosylated hemoglobin A1c (HbA1c) levels are used as an indicator of average plasma glucose concentration in diabetic patients. Levels of more than 48 mmol/mol (6.5%) are used as a criterion for the diagnosis of diabetes. Higher levels of HbA1c are also associated with cardiovascular disease.
Application Notes: This antibody is recommended for detection of HbA1c levels in plasma and blood samples. The binding reactivity of this antibody towards HbA1c and non-glycated hemoglobin was done using indirect ELISA. The binding reactivity of this antibody to HbA1c was compared to commercially available anti-HbA1c antibody BM300-F7C2 and it was reported that this antibody showed better specificity for HbA1c (CN110724671).
Antibody first published in: PMID: